-
公开(公告)号:US20230305010A1
公开(公告)日:2023-09-28
申请号:US18309985
申请日:2023-05-01
Applicant: Roche Diagnostics Operations, Inc.
Inventor: Farshid Dayyani , Anika Mang , David Morgenstern , Vinzent Rolny , Magdalena Swiatek-De Lange
IPC: G01N33/574
CPC classification number: G01N33/57438 , G01N2333/8146 , G01N2333/96494 , G01N2470/04 , G01N2800/50 , G01N2800/08
Abstract: The present invention relates to an in vitro method for assessing cholangiocarcinoma in a patient sample, comprising the steps of: a) determining the level of tissue inhibitor of metalloproteinase-1 (TIMP1) in the patient sample, wherein the patient sample is selected from a group consisting of serum, plasma and whole blood sample from an individual, b) comparing the level of TIMP1 determined in step (a) with a reference level of TIMP1, and c) assessing cholangiocarcinoma in the patient sample by comparing the level determined in step (a) to the reference level of TIMP1, wherein an increased level of TIMP1 compared to the reference level of TIMP1 is indicative for cholangiocarcinoma in the patient sample. Further, the present invention relates to an in vitro method for assessing cholangiocarcinoma comprising TIMP1 and MMP2, the use of TIMP1 and optionally MMP2 in the in vitro assessment of CCA, and a kit for performing the said methods.